Epidemiologic Trends and Determinants of Advanced HIV Disease among People Living with HIV in Zimbabwe (2017-2024): Evidence to Inform an Optimisation Framework
Abstract:
Advanced
HIV Disease (AHD) remains a leading cause of morbidity and mortality among
people living with HIV (PLHIV) despite widespread antiretroviral therapy (ART)
coverage. This study analysed epidemiologic trends and facility-level
determinants of AHD in Zimbabwe to inform targeted programme optimisation
strategies. A retrospective analysis of routine District Health Information
System 2 (DHIS2) data was conducted across 16 health facilities in Harare and
Mashonaland East from 2017 to 2024. AHD was defined in accordance with
contemporaneous World Health Organization guidelines, and analyses included
descriptive statistics, temporal trend assessment, geographic comparisons,
correlation, and multivariable regression. Among 495,166 PLHIV on ART, 4,169
AHD cases were identified. AHD prevalence followed a U-shaped trend, declining
from 20.31% in 2017 to 2.20% in 2020, before rising to 16.12% in 2024,
reflecting programmatic shifts and COVID-19 disruptions. Rural Mashonaland East
recorded significantly higher prevalence than urban Harare (16.53% vs. 9.71%,
p=0.002). Facility-level variation was substantial (0.56%–40.23%), with
district hospitals bearing a disproportionate burden (β = 15.24, p = 0.001).
AHD was positively associated with cryptococcal meningitis (r = 0.419, p =
0.003) and mortality (r = 0.385, p = 0.007), while loss to follow-up was not
strongly correlated. Despite strong retention outcomes, persistent challenges
in early diagnosis and AHD identification remain. Geographic and facility-level
inequities underscore the need for differentiated, equity-focused
interventions. Strengthening decentralised screening, particularly for
opportunistic infections such as cryptococcal disease and tuberculosis, is
essential to reduce preventable mortality and improve clinical outcomes.
References:
[1].
Ahmed, A., Desta, A., Gebremedhin, T.,
2023, Late presentation for HIV care in sub-Saharan Africa: a systematic review
and meta-analysis. BMJ Global Health, 8(1), e010481.
[2].
Geng, E. H., Odeny, T. A., Lyamuya, R.,
Holmes, C. B., 2021, Retention in care and patient-reported reasons for
undocumented transfer or stopping care among HIV-infected patients on
antiretroviral therapy in Eastern Africa: Application of a sampling-based
approach. Clinical Infectious Diseases, 72(Suppl 1), S1–S8.
[3].
Gonese, E., Dzangare, J., Takarinda, K.
C., et al., 2020, High HIV prevalence and incidence inequalities amongst key
populations in Zimbabwe: a case for differentiated service delivery. Journal
of the International AIDS Society, 23(Suppl 1), e25506.
[4].
Hatzold, K., Ahmed, N., Gudukeya, S.,
2022, Impact of COVID-19 on HIV service delivery: lessons from Zimbabwe. The
Lancet HIV, 9(1), e2–e3.
[5].
Huerga, H., Rucker, S., Cossa, L., et
al., 2022, Advanced HIV disease at presentation to care in Mozambique and
Zimbabwe: A cross-sectional study. PLOS Global Public Health, 2(1),
e0000105.
[6].
ICAP, 2023, Differentiated Service
Delivery for HIV Treatment: A Toolkit for Implementation. Columbia
University Mailman School of Public Health.
[7].
Jewell, B. L., Mudimu, E., Stover, J.,
et al., 2020, Potential effects of disruption to HIV programs in sub-Saharan
Africa caused by COVID-19: results from multiple mathematical models. The
Lancet HIV, 7(9), e629–e640.
[8].
Kerkhoff, A. D., Barr, D. A., Schutz,
C., et al., 2023, Disseminated tuberculosis among hospitalised HIV patients in
South Africa: a common condition that can be rapidly diagnosed using
urine-based assays. Scientific Reports, 13, 112.
[9].
Larson, B. A., Schnippel, K., Ndibongo,
B., et al., 2022, Rapid point-of-care CD4 testing at mobile units and linkage
to HIV care: an evaluation of community-based mobile HIV testing in South
Africa. AIDS Research and Therapy, 19(1), 1.
[10]. Mee,
P., Rice, B., Duda, S., et al., 2022, Advanced HIV disease in the
antiretroviral therapy era: a review. Current Opinion in HIV and AIDS,
17(3), 145–152.
[11]. Moyo,
C., Chikwanha, T. M., Moyo, F., 2021, Use of routine health data in low- and
middle-income countries: a review of current literature and future directions. Health
Policy and Planning, 36(Supplement_1), i1–i4.
[12]. Mukwenha,
S., Dzinamarira, T., Musuka, G., 2022, Impact of multi-month dispensing on HIV
treatment outcomes in Zimbabwe. AIDS Research and Therapy, 19(1), 55.
[13]. Mungati,
M., Dube, S., Mugurungi, O., et al., 2021, Geospatial heterogeneity of HIV and
associated factors in Zimbabwe: a nationwide population-based study. BMJ
Open, 11(12), e055312.
[14]. Mutevedzi,
P. C., Lessells, R. J., Rodger, A. J., et al., 2020, Association of age with
mortality and virological and immunological response to antiretroviral therapy
in rural South African adults. PLOS ONE, 15(7), e0234789.
[15]. Phillips,
A. N., Bansi-Matharu, L., Cambiano, V., 2023, The potential impact of emerging
technologies in the management of advanced HIV disease. Current Opinion in
HIV and AIDS, 18(2), 87–94.
[16]. Shamu,
S., Farirai, T., Slabbert, J., et al., 2021, Socio-economic and demographic
factors associated with late HIV diagnosis in rural South Africa. Southern
African Journal of HIV Medicine, 22(1), 1198.
[17]. Takarinda,
K. C., Harries, A. D., Shiraishi, R. W., et al., 2020, Gender-related
differences in outcomes and attrition on antiretroviral therapy among an
HIV-infected patient cohort in Zimbabwe: 2007–2010. International Journal of
Infectious Diseases, 90, 34–41.
[18]. Tenforde,
M. W., Mokomane, M., Leeme, T., et al., 2022, Advanced HIV disease in Botswana
following successful antiretroviral therapy rollout: incidence of and temporal
trends in cryptococcal meningitis. Clinical Infectious Diseases,
74(Suppl 2), S172–S179.
[19]. World
Health Organization, 2021, Guidelines for managing advanced HIV disease and
rapid initiation of antiretroviral therapy. World Health Organization. https://www.who.int/publications/i/item/9789241550062
